Skip to Content

Triklo Capsules

Generic Name: omega-3-acid ethyl esters
Dosage Form: capsule, liquid filled

Medically reviewed on Dec 1, 2017

Indications and Usage for Triklo Capsules

Triklo Capsules are indicated as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe (≥500 mg/dL) hypertriglyceridemia (HTG).

Usage Considerations: Patients should be placed on an appropriate lipid-lowering diet before receiving Triklo Capsules and should continue this diet during treatment with Triklo Capsules.

Laboratory studies should be done to ascertain that the lipid levels are consistently abnormal before instituting therapy with Triklo Capsules. Every attempt should be made to control serum lipids with appropriate diet, exercise, weight loss in obese patients, and control of any medical problems such as diabetes mellitus and hypothyroidism that are contributing to the lipid abnormalities. Medications known to exacerbate hypertriglyceridemia (such as beta blockers, thiazides, estrogens) should be discontinued or changed if possible prior to consideration of triglyceride-lowering drug therapy.

Limitations of Use:

The effect of Triklo Capsules on the risk for pancreatitis has not been determined.

The effect of Triklo Capsules on cardiovascular mortality and morbidity has not been determined.

Triklo Capsules Dosage and Administration

  • Assess triglyceride levels carefully before initiating therapy. Identify other causes (e.g., diabetes mellitus, hypothyroidism, or medications) of high triglyceride levels and manage as appropriate [see Indications and Usage (1)].
  • Patients should be placed on an appropriate lipid-lowering diet before receiving Triklo Capsules, and should continue this diet during treatment with Triklo Capsules. In clinical studies, Triklo Capsules were administered with meals.

The daily dose of Triklo Capsules is 4 grams per day. The daily dose may be taken as a single 4-gram dose (4 capsules) or as two 2-gram doses (2 capsules given twice daily).

Patients should be advised to swallow Triklo Capsules whole. Do not break open, crush, dissolve, or chew Triklo Capsules.

Dosage Forms and Strengths

Triklo Capsules are supplied as 1 gram transparent, soft-gelatin capsules filled with light-yellow oil and imprinted with "AN34".

Contraindications

Triklo Capsules are contraindicated in patients with known hypersensitivity (e.g., anaphylactic reaction) to Triklo Capsules or any of its components.

Warnings and Precautions

Monitoring: Laboratory Tests

In patients with hepatic impairment, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels should be monitored periodically during therapy with Triklo Capsules. In some patients, increases in ALT levels without a concurrent increase in AST levels were observed.

In some patients, Triklo Capsules increase LDL-C levels. LDL-C levels should be monitored periodically during therapy with Triklo Capsules.

Laboratory studies should be performed periodically to measure the patient's TG levels during therapy with Triklo Capsules.

Fish Allergy

Triklo Capsules contain ethyl esters of omega-3 fatty acids (EPA and DHA) obtained from the oil of several fish sources. It is not known whether patients with allergies to fish and/or shellfish, are at increased risk of an allergic reaction to Triklo Capsules. Triklo Capsules should be used with caution in patients with known hypersensitivity to fish and/or shellfish.

Recurrent Atrial Fibrillation (AF) or Flutter

In a double-blind, placebo-controlled trial of 663 subjects with symptomatic paroxysmal AF (n=542) or persistent AF (n=121), recurrent AF or flutter was observed in subjects randomized to Triklo Capsules who received 8 grams/day for 7 days and 4 grams/day thereafter for 23 weeks at a higher rate relative to placebo. Subjects in this trial had median baseline triglycerides of 127 mg/dL, had no substantial structural heart disease, were taking no anti-arrhythmic therapy (rate control permitted), and were in normal sinus rhythm at baseline.

At 24 weeks, in the paroxysmal AF stratum, there were 129 (47%) first recurrent symptomatic AF or flutter events on placebo and 141 (53%) on Triklo Capsules [primary endpoint, HR 1.19; 95% CI: 0.93, 1.35]. In the persistent AF stratum, there were 19 (35%) events on placebo and 34 (52%) events on Triklo Capsules [HR 1.63; 95% CI: 0.91, 2.18]. For both strata combined, the HR was 1.25; 95% CI: 1, 1.4. Although the clinical significance of these results is uncertain, there is a possible association between Triklo Capsules and more frequent recurrences of symptomatic atrial fibrillation or flutter in patients with paroxysmal or persistent atrial fibrillation, particularly within the first 2 to 3 months of initiating therapy.

Triklo Capsules are not indicated for the treatment of AF or flutter.

Adverse Reactions

Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Adverse reactions reported in at least 3% and at a greater rate than placebo for subjects treated with omega-3-acid ethyl esters based on pooled data across 23 clinical trials are listed in Table 1.

Table 1. Adverse Reactions Occurring at Incidence ≥3% and Greater than Placebo in Clinical Trials of Omega-3-acid ethyl esters
Omega-3-acid ethyl esters
(N = 655)
Placebo
(N = 370)
Adverse Reaction* n % n %
*
Studies included subjects with HTG and severe HTG.
Eructation 29 4 5 1
Dyspepsia 22 3 6 2
Taste perversion 27 4 1 <1

Additional adverse reactions from clinical trials are listed below:

Digestive System: Constipation, gastrointestinal disorder and vomiting.

Metabolic and Nutritional Disorders: Increased ALT and increased AST.

Skin: Pruritus and rash

Postmarketing Experience

In addition to adverse reactions reported from clinical trials, the events described below have been identified during post-approval use of omega-3-acid ethyl esters. Because these events are reported voluntarily from a population of unknown size, it is not possible to reliably estimate their frequency or to always establish a causal relationship to drug exposure.

The following events have been reported: anaphylactic reaction, hemorrhagic diathesis.

Drug Interactions

Anticoagulants or Other Drugs Affecting Coagulation

Some trials with omega-3-acids demonstrated prolongation of bleeding time. The prolongation of bleeding time reported in these trials has not exceeded normal limits and did not produce clinically significant bleeding episodes. Clinical trials have not been done to thoroughly examine the effect of Triklo Capsules and concomitant anticoagulants. Patients receiving treatment with Triklo Capsules and an anticoagulant or other drug affecting coagulation (e.g., anti-platelet agents) should be monitored periodically.

USE IN SPECIFIC POPULATIONS

Pregnancy

Pregnancy Category C: There are no adequate and well-controlled studies in pregnant women. It is unknown whether Triklo Capsules can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity. Triklo Capsules should be used during pregnancy only if the potential benefit to the patient justifies the potential risk to the fetus.

Animal Data: Triklo Capsules have been shown to have an embryocidal effect in pregnant rats when given in doses resulting in exposures 7 times the recommended human dose of 4 grams/day based on a body surface area comparison.

In female rats given oral gavage doses of 100, 600, and 2,000 mg/kg/day beginning 2 weeks prior to mating and continuing through gestation and lactation, no adverse effects were observed in the high-dose group (5 times human systemic exposure following an oral dose of 4 grams/day based on body surface area comparison).

In pregnant rats given oral gavage doses of 1,000, 3,000, and 6,000 mg/kg/day from gestation day 6 through 15, no adverse effects were observed (14 times human systemic exposure following an oral dose of 4 grams/day based on a body surface area comparison).

In pregnant rats given oral gavage doses of 100, 600, and 2,000 mg/kg/day from gestation day 14 through lactation day 21, no adverse effects were seen at 2,000 mg/kg/day (5 times the human systemic exposure following an oral dose of 4 grams/day based on a body surface area comparison). However, decreased live births (20% reduction) and decreased survival to postnatal day 4 (40% reduction) were observed in a dose-ranging study using higher doses of 3,000 mg/kg/day (7 times the human systemic exposure following an oral dose of 4 grams/day based on a body surface area comparison).

In pregnant rabbits given oral gavage doses of 375, 750, and 1,500 mg/kg/day from gestation day 7 through 19, no findings were observed in the fetuses in groups given 375 mg/kg/day (2 times human systemic exposure following an oral dose of 4 grams/day based on a body surface area comparison). However, at higher doses, evidence of maternal toxicity was observed (4 times human systemic exposure following an oral dose of 4 grams/day based on a body surface area comparison).

Nursing Mothers

Studies with Triklo Capsules have demonstrated excretion in human milk. The effect of this excretion on the infant of a nursing mother is unknown; caution should be exercised when Triklo Capsules are administered to a nursing mother. An animal study in lactating rats given oral gavage 14C-ethyl EPA demonstrated that drug levels were 6 to 14 times higher in milk than in plasma.

Pediatric Use

Safety and effectiveness in pediatric patients have not been established.

Geriatric Use

A limited number of subjects older than 65 years were enrolled in the clinical trials of Triklo Capsules. Safety and efficacy findings in subjects older than 60 years did not appear to differ from those of subjects younger than 60 years.

Drug Abuse and Dependence

Triklo Capsules do not have any known drug abuse or withdrawal effects.

Triklo Capsules Description

Triklo Capsules, a lipid-regulating agent, are supplied as a liquid-filled gel capsule for oral administration. Each 1 gram capsule of Triklo Capsules contains at least 900 mg of the ethyl esters of omega-3 fatty acids sourced from fish oils. These are predominantly a combination of ethyl esters of eicosapentaenoic acid (EPA - approximately 465 mg) and docosahexaenoic acid (DHA - approximately 375 mg).

The empirical formula of EPA ethyl ester is C22H34O2, and the molecular weight of EPA ethyl ester is 330.51. The structural formula of EPA ethyl ester is:

The empirical formula of DHA ethyl ester is C24H36O2, and the molecular weight of DHA ethyl ester is 356.55. The structural formula of DHA ethyl ester is:

Triklo Capsules also contain the following inactive ingredients: alpha-tocopherol, gelatin, glycerin and purified water (components of the capsule shell).

Triklo Capsules - Clinical Pharmacology

Mechanism of Action

The mechanism of action of Triklo Capsules is not completely understood. Potential mechanisms of action include inhibition of acyl-CoA:1,2-diacylglycerol acyltransferase, increased mitochondrial and peroxisomal β-oxidation in the liver, decreased lipogenesis in the liver, and increased plasma lipoprotein lipase activity. Triklo Capsules may reduce the synthesis of triglycerides in the liver because EPA and DHA are poor substrates for the enzymes responsible for TG synthesis, and EPA and DHA inhibit esterification of other fatty acids.

Pharmacokinetics

In healthy volunteers and in subjects with hypertriglyceridemia, EPA and DHA were absorbed when administered as ethyl esters orally. Omega-3-acids administered as ethyl esters (Triklo Capsules) induced significant, dose-dependent increases in serum phospholipid EPA content, though increases in DHA content were less marked and not dose-dependent when administered as ethyl esters.

Specific Populations:

Age: Uptake of EPA and DHA into serum phospholipids in subjects treated with Triklo Capsules was independent of age (<49 years versus ≥49 years).

Gender: Females tended to have more uptake of EPA into serum phospholipids than males. The clinical significance of this is unknown.

Pediatric: Pharmacokinetics of Triklo Capsules have not been studied.

Renal or Hepatic Impairment: Triklo Capsules have not been studied in patients with renal or hepatic impairment.

Drug-Drug Interactions:

Simvastatin: In a 14-day trial of 24 healthy adult subjects, daily co-administration of simvastatin 80 mg with Triklo Capsules 4 grams did not affect the extent (AUC) or rate (Cmax) of exposure to simvastatin or the major active metabolite, beta-hydroxy simvastatin at steady-state.

Atorvastatin: In a 14-day trial of 50 healthy adult subjects, daily co-administration of atorvastatin 80 mg with Triklo Capsules 4 grams did not affect AUC or Cmax of exposure to atorvastatin, 2-hydroxyatorvastatin, or 4-hydroxyatorvastatin at steady-state.

Rosuvastatin: In a 14-day trial of 48 healthy adult subjects, daily co-administration of rosuvastatin 40 mg with Triklo Capsules 4 grams did not affect AUC or Cmax of exposure to rosuvastatin at steady-state.

In vitro studies using human liver microsomes indicated that clinically significant cytochrome P450-mediated inhibition by EPA/DHA combinations are not expected in humans.

Nonclinical Toxicology

Carcinogenesis, Mutagenesis, Impairment of Fertility

In a rat carcinogenicity study with oral gavage doses of 100, 600, and 2,000 mg/kg/day, males were treated with Triklo Capsules for 101 weeks and females for 89 weeks without an increased incidence of tumors (up to 5 times human systemic exposures following an oral dose of 4 grams/day based on a body surface area comparison). Standard lifetime carcinogenicity bioassays were not conducted in mice.

Triklo Capsules were not mutagenic or clastogenic with or without metabolic activation in the bacterial mutagenesis (Ames) test with Salmonella typhimurium and Escherichia coli or in the chromosomal aberration assay in Chinese hamster V79 lung cells or human lymphocytes. Triklo Capsules were negative in the in vivo mouse micronucleus assay.

In a rat fertility study with oral gavage doses of 100, 600, and 2,000 mg/kg/day, males were treated for 10 weeks prior to mating and females were treated for 2 weeks prior to and throughout mating, gestation and lactation. No adverse effect on fertility was observed at 2,000 mg/kg/day (5 times human systemic exposure following an oral dose of 4 grams/day based on a body surface area comparison).

Clinical Studies

Severe Hypertriglyceridemia

The effects of omega-3-acid ethyl esters 4 grams per day were assessed in 2 randomized, placebo-controlled, double-blind, parallel-group trials of 84 adult subjects (42 on omega-3-acid ethyl esters, 42 on placebo) with very high triglyceride levels. Subjects whose baseline triglyceride levels were between 500 and 2,000 mg/dL were enrolled in these 2 trials of 6 and 16 weeks' duration. The median triglyceride and LDL-C levels in these subjects were 792 mg/dL and 100 mg/dL, respectively. Median HDL-C level was 23 mg/dL.

The changes in the major lipoprotein lipid parameters for the groups receiving omega-3-acaid ethyl esters or placebo are shown in Table 2.

Table 2. Median Baseline and Percent Change From Baseline in Lipid Parameters in Subjects With Severe Hypertriglyceridemia (≥500 mg/dL)
Parameter Omega-3-acid ethyl esters
N = 42
Placebo
N = 42
Difference
BL % Change BL % Change
BL = Baseline (mg/dL); % Change = Median Percent Change from Baseline; Difference = Omega-3-acid ethyl esters Median % Change – Placebo Median % Change.
TG 816 -44.9 788 +6.7 -51.6
Non-HDL-C 271 -13.8 292 -3.6 -10.2
TC 296 -9.7 314 -1.7 -8
VLDL-C 175 -41.7 175 -0.9 -40.8
HDL-C 22 +9.1 24 0 +9.1
LDL-C 89 +44.5 108 -4.8 +49.3

Omega-3-acid ethyl esters 4 grams per day reduced median TG, VLDL-C, and non-HDL-C levels and increased median HDL-C from baseline relative to placebo. Treatment with Triklo Capsules to reduce very high TG levels may result in elevations in LDL-C and non-HDL-C in some individuals. Patients should be monitored to ensure that the LDL-C level does not increase excessively.

The effect of Triklo Capsules on the risk of pancreatitis has not been determined.

The effect of Triklo Capsules on cardiovascular mortality and morbidity has not been determined.

How Supplied/Storage and Handling

Triklo Capsules (omega-3-acid ethylesters capsules, USP) are supplied as 1 gram, transparent, soft-gelatin capsules filled with light-yellow oil and imprinted with "AN34".

They are available as follows:

Bottles of 60 capsules: NDC 70868-150-60
Bottles of 120 capsules: NDC 70868-150-12

Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature]. Do not freeze. Dispense in a tight, light-resistant container. Protect from light. Keep out of reach of children.

Patient Counseling Information

Advise the patient to read the FDA-approved patient labeling (Patient Information).

Information for Patients

  • Triklo Capsules should be used with caution in patients with known sensitivity or allergy to fish and/or shellfish [see Warnings and Precautions (5.2)].
  • Advise patients that use of lipid-regulating agents does not reduce the importance of adhering to diet [see Dosage and Administration (2)].
  • Advise patients not to alter Triklo Capsules capsules in any way and to ingest intact capsules only [see Dosage and Administration (2)].
  • Instruct patients to take Triklo Capsules as prescribed. If a dose is missed, advise patients to take it as soon as they remember. However, if they miss one day of Triklo Capsules, they should not double the dose when they take it.

Manufactured for:
Key Therapeutics, LLC
Flowood, MS 39232

Distributed by:
Allegis Pharmaceuticals, LLC
Canton, MS 39046

Rev. 08/17

PRINCIPAL DISPLAY PANEL - 1 gram Capsule Bottle Label

NDC 70868-150-60

Triklo Capsules
(omega-3-acid ethyl
esters capsules, USP)

1 gram*

Swallow
capsules whole.

KEY
therapeutics

Rx Only

60 Capsules

TRIKLO 
omega-3-acid ethyl esters capsule, liquid filled
Product Information
Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:70868-150
Route of Administration ORAL DEA Schedule     
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
OMEGA-3-ACID ETHYL ESTERS (OMEGA-3 FATTY ACIDS) OMEGA-3-ACID ETHYL ESTERS 1 g
Inactive Ingredients
Ingredient Name Strength
GELATIN, UNSPECIFIED  
GLYCERIN  
WATER  
.ALPHA.-TOCOPHEROL  
Product Characteristics
Color YELLOW (yellow clear) Score no score
Shape CAPSULE Size 23mm
Flavor Imprint Code AN34
Contains     
Packaging
# Item Code Package Description
1 NDC:70868-150-60 60 CAPSULE, LIQUID FILLED in 1 BOTTLE
2 NDC:70868-150-12 120 CAPSULE, LIQUID FILLED in 1 BOTTLE
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
ANDA ANDA204940 08/08/2017
Labeler - Key Therapeutics, LLC (080318791)
 
Key Therapeutics, LLC
Hide